Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01091428 · ClinicalTrials.gov registry record · Phase 2
Alisertib (MLN8237) in Participants With Ovarian, Fallopian Tube or Peritoneal Cancer Preceded by Phase 1 Study of MLN8237 Plus Paclitaxel Treatment of Ovary or Breast Cancer
A Phase 2 study, sponsored by Millennium Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 191
- Enrollment target
NCT01091428 is a Phase 2 study that has completed, run by Millennium Pharmaceuticals. The registered enrollment target is 191 participants.
The verdict
NCT01091428, a Phase 2 study, has completed, sponsored by Millennium Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 191 participants
- Enrollment target
Study Summary
This is an open-label, multicenter study with a nonrandomized Phase 1 portion and an open-label, randomized, Phase 2 portion evaluating MLN8237 in combination with weekly paclitaxel in adult female participants with advanced breast cancer (Phase 1 portion only) and recurrent ovarian cancer (both Phase 1 and Phase 2 portions).
Interventions
- DRUG Paclitaxel
- DRUG Alisertib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 191 participants |
| Start Date | 2010-04-16 |
| Est. Completion | 2017-07-19 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01091428
The ClinicalTrials.gov registry entry for NCT01091428 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 191 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Millennium Pharmaceuticals, which has 135 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Paclitaxel is the first listed.
NCT01091428 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01091428 about?
NCT01091428 is a clinical study titled "Alisertib (MLN8237) in Participants With Ovarian, Fallopian Tube or Peritoneal Cancer Preceded by Phase 1 Study of MLN8237 Plus Paclitaxel Treatment of Ovary or Breast Cancer". This is an open-label, multicenter study with a nonrandomized Phase 1 portion and an open-label, randomized, Phase 2 portion evaluating MLN8237 in combination with weekly paclitaxel in adult female participants with advanced breast cancer (Phase 1 portion only) and recurrent ovarian cancer (both Pha...
What is the current status of trial NCT01091428?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 191 participants. The study started on 2010-04-16. Estimated completion is 2017-07-19.
What interventions are being tested in trial NCT01091428?
The interventions under investigation include: Paclitaxel (DRUG), Alisertib (DRUG).
Who is sponsoring clinical trial NCT01091428?
This trial is sponsored by Millennium Pharmaceuticals, which has 135 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.